Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy

Fineline Cube Jan 23, 2026
Company Deals

Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base

Fineline Cube Jan 23, 2026
Company Deals

BD and Ypsomed Develop Neopak XtraFlow 5.5mL Prefilled Syringe for YpsoMate Auto‑Injector

Fineline Cube Jan 23, 2026
Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6‑Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer

Fineline Cube Jan 23, 2026
Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026
Company Drug

Shanghai Haihe Pharmaceutical’s Glumetinib Filed for Marketing in Japan for NSCLC Treatment

Fineline Cube Sep 8, 2023

Shanghai Haihe Pharmaceutical Co., Ltd has announced the filing for marketing approval in Japan for...

Company

Eminence Biotechnology Launches Fully Operational Cell Culture Media Facility in Suzhou

Fineline Cube Sep 8, 2023

China-based Eminence Biotechnology (Suzhou) Co., Ltd. has announced the full operation of its state-of-the-art cell...

Company Medical Device

LIQUIK Study Interim Results to Showcase Lucence’s Liquid Biopsy Advancements at WCLC 2023

Fineline Cube Sep 8, 2023

Precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto, California,...

Company Drug

Luye Pharma’s Botawei Receives NMPA Approval for Breast Cancer Treatment

Fineline Cube Sep 8, 2023

Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...

Company Deals

ClouDr Partners with Hong Kong Magicure Medical Center to Enhance Cross-Border Medical Access

Fineline Cube Sep 8, 2023

Hangzhou Kang Ming Information Technology Co., Ltd, known as “ClouDr” (HKG: 9955), has entered into...

Company Medical Device

Mindray Launches TE Air Wireless Handheld Ultrasound Solution in the US Market

Fineline Cube Sep 8, 2023

China-based global device giant Mindray (SHE: 300760) has announced the market launch of its TE...

Company

MSD Plans to Introduce Over 50 New Drugs and Vaccines to China in the Next Five Years

Fineline Cube Sep 8, 2023

Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK), through its China R&D president Li Zhengqing,...

Company Deals R&D

Novo Nordisk and Broad Institute Collaborate on Diabetes and Cardiometabolic Research

Fineline Cube Sep 7, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a collaboration with the US academic...

Company Drug

Janssen’s Rybrevant Combo Meets Primary Endpoint in Advanced NSCLC Study

Fineline Cube Sep 7, 2023

Janssen, a subsidiary of Johnson & Johnson (J&J; NYSE: JNJ), has released an update on...

Company Policy / Regulatory

FDA Addresses Looming Migraine Treatment Shortage with Tonix Pharmaceuticals Commitment

Fineline Cube Sep 7, 2023

The US Food and Drug Administration (FDA) is actively engaging with pharmaceutical companies to address...

Company Drug

Henan Zhongshuai’s Dexmethylphenidate Hydrochloride Capsules Target Priority Review for Pediatric ADHD

Fineline Cube Sep 7, 2023

Henan Zhongshuai Pharmaceutical Co., Ltd., a China-based pharmaceutical company, is poised to secure priority review...

Company Drug

Amneal Pharmaceuticals Receives China Approval for Sevelamer Carbonate

Fineline Cube Sep 7, 2023

US-based Amneal Pharmaceuticals Inc. (NYSE: AMRX) has announced that it has received approval from the...

Company Drug

CSPC Pharmaceutical’s Narlumosbart Approved by NMPA for Bone Giant Cell Tumors

Fineline Cube Sep 7, 2023

CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its subsidiary, Shanghai JMT Biotechnology Co.,...

Company Drug

Jiangsu Hengrui’s HER2-Targeted ADC SHR-A1811 Aims for CDE’s BTD Status

Fineline Cube Sep 7, 2023

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its HER2 targeted antibody-drug...

Policy / Regulatory

NMPA Drafts Guidelines for Supervising Online Drug Exchange Platforms

Fineline Cube Sep 7, 2023

The National Medical Products Administration (NMPA) has released draft “Online Third-party Drug Exchange Platforms Inspection...

Company Drug

Genentech Files for FDA Approval of Crovalimab for PNH, Challenging Soliris

Fineline Cube Sep 7, 2023

Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has submitted its anti-C5 investigational drug, crovalimab,...

Company Deals

uBriGene and YolTech Therapeutics Join Forces to Advance mRNA Therapy and Gene Therapy

Fineline Cube Sep 7, 2023

China-based uBriGene Biosciences Inc., a prominent contract development and manufacturing organization (CDMO) specializing in cell...

Policy / Regulatory

CDE’s 2022 Drug Review Report: A Year of Pandemic Response and Regulatory Milestones

Fineline Cube Sep 7, 2023

The Center for Drug Evaluation (CDE) has released its comprehensive 2022 annual drug review report,...

Company Drug

Hainan Haiyao Concludes Phase I Clinical Study for PaiEnJiaBin, a Novel KCNQ Agonist

Fineline Cube Sep 7, 2023

China-based Hainan Haiyao Co., Ltd (SHE: 000566) has announced the conclusion of Phase I clinical...

Company Deals

Sino Medical Sciences Technology to Acquire Majority Stake in US Endovascular Device Firm eLum

Fineline Cube Sep 7, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced plans to acquire a 72.73%...

Posts pagination

1 … 424 425 426 … 613

Recent updates

  • Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6‑Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer
  • Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy
  • Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base
  • BD and Ypsomed Develop Neopak XtraFlow 5.5mL Prefilled Syringe for YpsoMate Auto‑Injector
  • Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6‑Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer

Company Deals

Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy

Company Deals

Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base

Company Deals

BD and Ypsomed Develop Neopak XtraFlow 5.5mL Prefilled Syringe for YpsoMate Auto‑Injector

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.